Status:
COMPLETED
Rosuvastatin in Rheumatoid Arthritis (RORA)
Lead Sponsor:
University of Dundee
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
40+ years
Phase:
PHASE2
PHASE3
Brief Summary
Patients with rheumatoid arthritis are at increased risk of having cardiovascular deaths. The investigator's study is aimed at looking at the effects of proven cholesterol lowering treatment drug call...
Eligibility Criteria
Inclusion
- Patients will be selected from a high risk population of hospital clinic attendees, defined as RA greater than 5 years' disease duration, and all will be RA latex seropositive or IgM RF ELISA \>14iu/ml. The subjects will be of either sex and \>40 years of age.
- Patients should have both tender and swollen joint counts \>4 each and either a CRP \>10mg/l, ESR \>25mm/h or PV \>1.78.
- Patients on cyclosporine or other medications known to be contraindicated with this form of drug will not be enrolled.
Exclusion
- The patient's hospital and general practice records will be scrutinised for evidence of symptomatic vascular disease.
- Any patient not free from vascular disease symptoms will be excluded.
- In addition to evidence of symptomatic vascular disease (either previous or current), the exclusion criteria consist also of those already taking lipid-lowering therapy or those with contraindications to these therapies.
- Also excluded will be subjects with a total cholesterol level of \>7.5mmol/L as it might be argued that such patients merit primary prevention on the basis of dyslipidemia alone.
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00679510
Start Date
February 1 2004
End Date
January 1 2008
Last Update
November 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Dundee
Dundee, United Kingdom